Plasma contact factors as therapeutic targets.

摘要: Abstract Direct oral anticoagulants (DOACs) are small molecule inhibitors of the coagulation proteases thrombin and factor Xa that demonstrate comparable efficacy to warfarin for several common indications, while causing less serious bleeding. However, because their targets required normal host-response bleeding (hemostasis), DOACs associated with therapy-induced limits use in certain patient populations clinical situations. The plasma contact factors (factor XII, XI, prekallikrein) initiate blood activated partial thromboplastin time assay. While serving limited roles hemostasis, pre-clinical epidemiologic data indicate these proteins contribute pathologic coagulation. It is anticipated drugs targeting will reduce risk thrombosis minimal impact on hemostasis. Here, we discuss biochemistry activation, contributions thrombosis, novel antithrombotic agents undergoing early testing.